BioMed Alliance response to the European Medicines Agency’s public consultation: Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products

The European Medicines Agency has released for public consultation a draft guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products.The BioMed Alliance replied to this consultation to convey the views of healthcare professionals and researchers.